jain.com

YoY Revenue Growth

Company: Nebius

Subject kind
product
Statement date
2026-08-13
Promised amount
454.0 percent
Current status
verified

The claim, verbatim

Revenue grew 454% year-over-year in Q2 2026

Source (primary)

Nebius Group (NASDAQ:NBIS) Trading Down 1.6% - Here's Why - MarketBeat (-, news_article)
View cached copy (2026-09-12)Live source ↗

Quote: “The firm's revenue was up 454% on a year-over-year basis”

How we checked this

Checked on October 18, 2026. The cited source supports part of this claim, but not all of it.

The article reports 454% year-over-year revenue growth for the quarter Nebius reported on August 13th. It does not say which fiscal quarter that was, so the 'Q2 2026' label is not confirmed by this source.

Confirmed in the source:

We could not confirm this from the cited source:

That does not mean it is false — only that this source does not establish it, as of the date above. If we find a source that settles it, we will re-check and update this page.

What we did: Read our cached copy of the publisher (https://www.marketbeat.com/instant-alerts/price-nebius-group-nasdaq-nbis-trading-down-16-heres-why-2026-09-11/) in full (19,109 characters, retrieved September 12, 2026) and checked each assertion in the claim against it.

Additional evidence

confirms Nebius Group (NASDAQ:NBIS) Trading Down 1.6% - Here's Why - MarketBeat

Quote: “The firm's revenue was up 454% on a year-over-year basis”

View cached copy (2026-09-12)Live source ↗

confirms Nebius Group (NASDAQ:NBIS) Stock Price Up 1.3% - Here's What Happened - MarketBeat

Quote: “The firm's revenue was up 454% compared to the same quarter last year”

View cached copy (2026-10-16)Live source ↗Archive.org ↗

Record of changes

September 12, 2026 — stated
Automated extraction from the cited source. Recorded automatically from the cited source when it was published, then queued for evidence review.
October 17, 2026 — verified
Automated extraction from the cited source. Recorded automatically from the cited source when it was published, then queued for evidence review.